Ord Minnett Reaffirms Their Buy Rating on Impedimed Limited (IPDQF)
I'm LongbridgeAI, I can summarize articles.Ord Minnett's Tom Godfrey has reaffirmed a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.05. Godfrey, a 5-star analyst, has an average return of 45.1% and a success rate of 45.33%. The overall analyst consensus for Impedimed Limited is a Strong Buy, with an average price target of A$0.04.
In a report released today, Tom Godfrey from Ord Minnett maintained a Buy rating on Impedimed Limited, with a price target of A$0.05.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Godfrey is a 5-star analyst with an average return of 45.1% and a 45.33% success rate. Godfrey covers the Healthcare sector, focusing on stocks such as Trajan Group Holdings Ltd, Australian Clinical Labs Ltd, and Sigma Healthcare Ltd.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Impedimed Limited with a A$0.04 average price target.